Curis Lifesciences H1 FY27 Consol Net Profit at ₹4.14 Cr on Revenue of ₹37.03 Cr
Curis Lifesciences reported consolidated revenue from operations of ₹37.03 crore for the half year ended September 30, 2026. Consolidated profit after tax attributable to owners stood at ₹4.14 crore, yielding an unannualized half-year EPS of ₹5.76. This period marks the first consolidation following the acquisition of a 51% stake in Uninova Lifesciences and 49.95% in Nigeria-based Curosun Pharmaceutical. Operating cash flows remained slightly negative at ₹(0.18) crore, influenced by working capital and inventory funding.
உச்சம் நம்பிக்கை
என்ன மாறியதுCuris Lifesciences declared its maiden consolidated financial results for H1 FY27 after acquiring Uninova Lifesciences and associate Curosun Pharmaceutical.
ஏன் இது முக்கியம்Demonstrates baseline consolidated performance, margin structure, and cash flows as the company expands operations domestically and into international markets.
Consolidated Revenue (H1 FY27): ₹3703.39 லட்சம்Consolidated PAT (H1 FY27): ₹413.98 லட்சம்Basic EPS (unannualized): ₹5.76Subsidiary Acquisition Cost (Uninova): ₹20,65,500Operating Cash Flow (H1 FY27): ₹(17.59) lakh
📅 குறுகிய காலம்Market focus will center on consolidated profitability versus prior standalone trends, alongside cash burn in working capital and investing capex.
📈 நீண்ட காலம்Integration of the newly added entities and sustained conversion of reported accrual profits into operational cash flow will determine structural growth.
⚠ அபாய எச்சரிக்கைகள்
- Negative operating cash flows of ₹17.59 lakh during the period
- First period of consolidation makes direct historical comparison limited
- Cash and cash equivalents fell sharply from ₹3.17 crore to ₹0.19 crore
👀 கவனிக்க வேண்டியவை
Monitor working capital absorption and cash flow generation, along with operational integration and contribution from newly acquired entities Uninova and Curosun in the H2 results.
